Kyverna therapeutics announces closing of initial public offering and full exercise of underwriters' option to purchase additional shares

Emeryville, calif. , feb. 12, 2024 /prnewswire/ -- kyverna therapeutics, inc. (kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced the closing of its upsized initial public offering of 16,675,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 2,175,000 additional shares, at an initial public offering price of $22.00 per share.
KYTX Ratings Summary
KYTX Quant Ranking